TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20099350
Drug: 1 mL/second
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL/second injection rate of gadoxetic acid
Study: 20099350
Drug: 2 mL/second
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL/second injection rate of gadoxetic acid
Study: 18294024
Drug: Olanzapine 5
Normalized name: olanzapine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 5 to 10 mg/day
Study: 18294024
Drug: Lamotrigine 50
Normalized name: lamotrigine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine 50 to 200 mg/day
Study: 17213049
Drug: Internet-based cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive-behavioral therapy (CBT) program; specific dosage and duration not mentioned.
Study: 14570627
Drug: Mannitol 1
Normalized name: mannitol 170 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol 1 g/kg added to the CPB prime
Study: 9007710
Drug: 6-month interferon
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month interferon alpha-2b therapy
Study: 9007710
Drug: 12-month interferon
Normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month interferon alpha-2b therapy
Study: 1889950
Drug: Naseptin antiseptic
Normalized name: Listerine Antiseptic
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naseptin antiseptic carrier cream
Study: 6362203
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose regimen (once-a-day application of fluocinonide combined with three-times-a-day application of its vehicle)
Study: 6362203
Drug: Traditional dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional dose regimen (four-times-a-day application of fluocinonide)
Study: 31962344
Drug: D1 agonist
Normalized name: PHOSPHOLIPASE D1
Approvals — FDA: no, EMA: no, PMDA: no
Description: D1 agonist (specific doses not mentioned)
Study: 31962344
Drug: D1 agonist
Normalized name: PHOSPHOLIPASE D1
Approvals — FDA: no, EMA: no, PMDA: no
Description: D1 agonist (higher doses)
Study: 24467565
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec (IDeg) 0.4 U/kg
Study: 23070990
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention (monthly Web-based conferences and articles on targeting care in RA)
Study: 18562432
Drug: Antidepressants (fluoxetine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (fluoxetine, duloxetine, or Hypericum perforatum)
Study: 9660334
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of anorganic bovine-derived hydroxyapatite matrix (ABM) and cell binding peptide (P-15)
Study: 9875874
Drug: Alendronate sodium
Normalized name: Alendronate Sodium
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate sodium (5 mg/d for 2 years, then 10 mg/d for the remainder of the trial)
Study: 2647398
Drug: CDP-Choline, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP-Choline, 500 mg twice a day orally for 2 to 8 weeks
Study: 28096223
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with pioglitazone plus weekly exenatide
Study: 29227578
Drug: Basal/bolus insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal/bolus insulin therapy
Study: 30537305
Drug: High-protein meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein meal (60 g protein)
Study: 30537305
Drug: Low-protein meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein meal (5 g protein)
Study: 17088142
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B nasal lavages (25 mL at 100 microg/mL, twice daily for 3 months)
Study: 15629023
Drug: Laser photo-coagulation
Normalized name: Coagulation factor XIa
DrugBank: Coagulation factor XIa (DB15420)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser photo-coagulation treatment
Study: 8113509
Drug: 5% lidocaine/prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% lidocaine/prilocaine cream (EMLA)
Study: 28626983
Drug: Test product
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test product (SM/FP) with 25/125 mcg per inhalation, 2, 6, and 12 inhalations
Study: 28626983
Drug: Reference product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product (SM/FP) with 25/125 mcg per inhalation, 2, 6, and 12 inhalations
Study: 26496366
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 μg/kg) with 0.75% ropivacaine and 2% lidocaine with adrenaline
Study: 18081733
Drug: Continuous interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous interferon alpha-2b therapy (1, 2 or 3 MIU TIW depending on response)
Study: 18081733
Drug: Cyclical interferon
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclical interferon alpha-2b therapy (3 MIU TIW for 24 weeks per relapse)
Study: 18081733
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (continuous and cyclical therapy)
Study: 14636196
Drug: Thiabendazole, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiabendazole, 20 mg/kg twice daily for 1 day, with repeat treatment after 10 days
Study: 12095157
Drug: Unfractionated Heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated Heparin (8 U/kg body wt per hour)
Study: 9687996
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (ST)
Study: 7505809
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) 5 micrograms/kg self-administered subcutaneously on days when chemotherapy was not given.
Study: 7505809
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm (no G-CSF) receiving weekly chemotherapy with cisplatin and etoposide alternating with ifosfamide and doxorubicin.
Study: 7505809
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) arm receiving weekly chemotherapy with G-CSF.
Study: 2679494
Drug: Nitrendipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (10 mg b.i.d. for 8 weeks)
Study: 28601084
Drug: Probiotic oral
Normalized name: Rezyst Probiotic Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic oral suspension (POS) for 3 weeks
Study: 22850326
Drug: 5 g/100
Normalized name: Zosyn, 4 g-0.5 g/100 mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g/100 g alginate
Study: 8442968
Drug: d‐tubocurarine (priming
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐tubocurarine (priming drug) + pancuronium (intubating dose) - Group C
Study: 8442968
Drug: pancuronium (priming
Approvals — FDA: no, EMA: no, PMDA: no
Description: pancuronium (priming drug) + d‐tubocurarine (intubating dose) - Group D
Study: 8442968
Drug: d‐tubocurarine (intubating
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐tubocurarine (intubating dose) - Groups B, D, and F
Study: 8442968
Drug: pancuronium (intubating
Approvals — FDA: no, EMA: no, PMDA: no
Description: pancuronium (intubating dose) - Groups A, C, and E
Study: 30796424
Drug: Targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted therapy (tyrosine kinase inhibitor for EGFR mutation-positive patients)
Study: 30796424
Drug: Targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted therapy (tyrosine kinase inhibitor for ALK-positive patients)
Study: 30796424
Drug: Chemotherapy monotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy monotherapy
Study: 22076253
Drug: Letrozole (5-year
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (5-year treatment)
Study: 18600358
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no drug or drain)
Study: 17486315
Drug: Rosiglitazone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (8 mg)
Study: 12351470
Drug: Glyburide (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide (15 mg)
Study: 15612515
Drug: Metformin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2 g)
Study: 12351470
Drug: Rosiglitazone, Glyburide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone, Glyburide, Metformin
Study: 12198782
Drug: Cued to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cued to form an image of a specified object (e.g., tiger)
Study: 7498100
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg cholecalciferol (vitamin D3)
Study: 1901204
Drug: Ceftriaxone sodium,
Normalized name: CefTRIAXone Sodium, 1 g injectable powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone sodium, 1 g/d intravenously
Study: 1901204
Drug: Cefamandole naftate
Normalized name: cefamandole naftate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole naftate and sodium carbonate, 1 g intravenously every 6 hours
Study: 30406883
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (Sham, 10 patients)
Study: 26331383
Drug: Vortioxetine (10/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine (10/20 mg)
Study: 26331383
Drug: Escitalopram (10/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10/20 mg)
Study: 23847964
Drug: Combined traditional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined traditional Chinese medicine and western medicine treatment (antivenom serum 6000 U for 5 days, anti pit viper No. 2 concentrated decoction 300 mL twice to three times daily for 5 days)
Study: 23847964
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine treatment (anti pit viper No. 2 concentrated decoction 300 mL twice to three times daily for 5 days)
Study: 23847964
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine treatment (antivenom serum 6000 U for 5 days)
Study: 20676771
Drug: Mesalamine 500
Normalized name: mesalamine 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine 500 mg suppository administered BID
Study: 20676771
Drug: Mesalamine 1
Normalized name: mesalamine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine 1 g suppository administered QHS
Study: 17315307
Drug: HsHMP (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: HsHMP (250 mg of total anthocyanins per dose)
Study: 2427843
Drug: Celiprolol 400
Normalized name: celiprolol 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol 400 mg once daily
Study: 3076609
Drug: Frone cream
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frone cream 20,000 IU/g
Study: 3076609
Drug: Frone cream
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frone cream or drops
Study: 3076609
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment of interferon in families
Study: 16677714
Drug: 250 mg/day
Normalized name: alpelisib 250 mg/day (200 mg x 1 and 50 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/day D-cycloserine (DCS)
Study: 14984380
Drug: 3 MU
Normalized name: Orasep Reformulated Dec 2013 Mucosal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 MU interferon‐alpha2b plus ribavirin (1000‐1200 mg) for 12 months (Group 1)
Study: 14984380
Drug: 3 MU
Normalized name: Orasep Reformulated Dec 2013 Mucosal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 MU interferon‐alpha2b plus ribavirin (1000‐1200 mg) for 12 months (Group 2)
Study: 28396565
Drug: Topical borneol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical borneol
Study: 24356256
Drug: Motavizumab 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motavizumab 30 mg/kg
Study: 24356256
Drug: Motavizumab 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motavizumab 100 mg/kg
Study: 22572834
Drug: Gut Balance™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gut Balance™ (synbiotic supplement)
Study: 12581548
Drug: Clarithromycin ER
Normalized name: Clarithromycin ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin ER 500-mg tablet QD for 7 days
Study: 12581548
Drug: Clarithromycin IR
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin IR 250-mg tablet BID for 7 days
Study: 9921849
Drug: Exercises performed
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercises performed at home (control treatment)
Study: 7478086
Drug: Pancuronium, Vecuronium,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium, Vecuronium, Atracurium (administered via intramuscular and intravascular routes)
Study: 377819
Drug: Fumaria-preparation Oddibil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fumaria-preparation Oddibil
Study: 30685166
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion initiated immediately after induction of anesthesia (n=33)
Study: 19332525
Drug: Deductive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deductive treatment (N = 16)
Study: 19332525
Drug: Inductive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inductive treatment (N = 16)
Study: 17879411
Drug: Ferrous succinate
Normalized name: Ferrous succinate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous succinate combined with triple therapy for H pylori eradication
Study: 15346355
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate (ISMO) at a dose of 20 mg twice a day for 2 weeks
Study: 15346355
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets for 2 weeks
Study: 9544901
Drug: rhGH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH therapy (all groups)
Study: 7911029
Drug: esmolol 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: esmolol 200 mg
Study: 7911029
Drug: esmolol 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: esmolol 100 mg
Study: 7439520
Drug: 2% sodium
Normalized name: Dextrose 5% and 0.2% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% sodium fusidate ointment
Study: 343991
Drug: Oral antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotic therapy (clindamycin, erythromycin, or flucloxacillin) plus placebo ointment
Study: 31560216
Drug: 1-month dual
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1-month dual antiplatelet therapy (DAPT)
Study: 26087080
Drug: Continuous terbinafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous terbinafine 250 mg daily for 12 weeks
Study: 26087080
Drug: Pulse terbinafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse terbinafine (3 pulses of 500 mg daily for a week, repeated every 4 weeks)
Study: 18283077
Drug: Asthma Agents
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Asthma Agents System (web-based data collection system)
Study: 11599156
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro (L1)
Study: 11599156
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro combined with 15% to 20% NPH (L2)
Study: 11599156
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular insulin treatment (Control)
Study: 9874860
Drug: Tramadol 25
Normalized name: traMADol 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 25 mg
Study: 9874860
Drug: Lidocaine 5
Normalized name: lidocaine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 5 mg
Study: 7978146
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% plain and triamcinolone acetonide 40 mg
Study: 4376998
Drug: Intensive intravenous
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive intravenous cyclophosphamide
Study: 4376998
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral Melphalan therapy
Study: 29039073
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard antiemetic treatment)
Study: 26585957
Drug: Weekly messages
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly messages comparing statin adherence to other participants (comparison)
Study: 26585957
Drug: Weekly summaries
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly summaries of statin adherence (summary)
Study: 26585957
Drug: Daily reports
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily reports to Medication Adherence Partner (MAP)
Study: 26585957
Drug: Weekly reports
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly reports to MAP
Study: 26585957
Drug: Reports to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reports to MAP only if dose was missed
Study: 24469527
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behavioral therapy for auditory verbal hallucinations (AVHs)
Study: 22947847
Drug: Whitening product
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whitening product used twice daily for 3 weeks
Study: 16320801
Drug: Garlic (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic (300 mg, containing 1.3% allicin, twice daily)
Study: 20353624
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical tablets)
Study: 12030110
Drug: Interferon-α2a 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-α2a 3.0 μ/m2 s.c. Monday, Wednesday, and Friday weeks 1-8; interleukin-2 11 μ/m2 s.c. Tuesday, Thursday and Saturday of weeks 1-4; cis-retinoic acid 1 mg/kg po daily weeks 1-8; 5-fluorouracil 750 mg/m2 IV weekly during weeks 5-8
Study: 9814639
Drug: fampridine-SR 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: fampridine-SR 12.5 and 17.5 mg b.i.d. over a 2-week treatment period
Study: 31711085
Drug: Bone graft
Normalized name: Bone graft material
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone graft group (bone graft placed between the implant and inferior alveolar nerve)
Study: 31711085
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (implants placed in direct contact with the inferior alveolar nerve)
Study: 28585585
Drug: Betamethasone Gel
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone Gel (0.05%)
Study: 28585585
Drug: Lidocaine Gel
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine Gel (4.0%)
Study: 8430921
Drug: Theophylline (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (two dosage levels)
Study: 2441648
Drug: Loperamide 0.4
Normalized name: loperamide 0.4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide 0.4 mg/kg/day
Study: 2441648
Drug: Loperamide 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide 0.8 mg/kg/day
Study: 30350717
Drug: Ocriplasmin injection
Normalized name: ocriplasmin Injection
DrugBank: Ocriplasmin (DB08888)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ocriplasmin injection (Jetrea®)
Study: 26181705
Drug: 12-week pharmacotherapy-based
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week pharmacotherapy-based algorithm treatment
Study: 17213002
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg administered at 3, 7, and 11 pm (total daily dose, 1200 mg)
Study: 14586357
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin (2 sprays of 400 mcg)
Study: 14586357
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 sprays)
Study: 10758957
Drug: Transmyocardial revascularization
Normalized name: ALCOHOL 80 mL in 100 mL TRANSENDOCARDIAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transmyocardial revascularization with CO2 laser (TMR) in addition to optimal medical treatment (MT)
Study: 10758957
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical treatment (MT)
Study: 8320424
Drug: Ipriflavone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipriflavone (600 mg/day) + calcium (500 mg/day)
Study: 16167916
Drug: Calcium (500
Normalized name: calcium gluconate 45 mg calcium (500 mg) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (500 mg/day)
Study: 3549990
Drug: Adriamycin (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adriamycin (70 mg/m2, slow push, every 3 weeks for seven courses, maximum 550 mg/m2)